Revenue totaled $201.2 million for the three months ended Jan. 31, up from $75.8 million for the year-ago period, and higher than the $200 million Street estimate.
Moving forward, HealthEquity said it anticipates FY21 revenue to be between $770 million and $790 million, and non-GAAP EPS in the range of $1.70 and $1.81. Wall Street was looking for $824.2 million of revenue and $1.80 of non-GAAP EPS.
Price: 41.00, Change: -3.15, Percent Change: -7.13
|Pilgrim's Pride Says It Will Fully Cooperate With US...|
|Alleghany's 2020 Estimate Scaled Up but Q2, and 2021...|
|Market Chatter: Evercore Partners Offers Incoming An...|
|Overnight Fixed Income Wrap: Bund Yields Up, Treasur...|
|Q2 Estimates for Dentsply Sirona Decreased, Forecast...|